Wednesday, June 19, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Ageing, Health & Rejuvenation Nature Conference in Rotterdam, on June 23rd. Insilico Medicine is also very proud to be one of the bronze sponsors of the event this year, which will give a unique opportunity to present our brand and to communicate with the most skilled people of ageing research. The event is jointly organised by Erasmus MC, Nature, Nature Medicine and Nature Reviews Molecular Cell Biology.
The conference brings together experts from diverse fields of research that explore the mechanisms of ageing and rejuvenation, from the perspective of genetics and epigenetics, cellular quality control and senescence, stem cells, metabolism and brain function. The aim of the conference is to foster interactions and stimulate discussion of recent and unpublished advances in our understanding of the ageing process, and to explore new therapeutic opportunities for the rejuvenation and preservation of organs and tissues to extend healthspan.
"We are happy to present our latest research at the Ageing, Health & Rejuvenation Nature Conference, which gathers the key scientists of the ageing research. The topic of machine learning implementation in drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
For further information, images or interviews, please contact:
Contact: Klug Gehilfe firstname.lastname@example.org
About Insilico Medicine, Inc
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
For more information about organisers:
Erasmus MC is a single organization with a single identity. All Erasmus MC units are presented with a common name, logo, and house style. The entire range of clinical services can be found here. We distinguish two sub-brands within Erasmus MC's single identity: Erasmus MC-Sophia Children's Hospital and Erasmus MC Cancer Institute. Both of these organizational units represent specialized fields with their own reputation in national and international university medical center healthcare. For more information: https:/
A weekly, international journal, publishing papers from any area of science with great potential impact and whose importance extends well beyond the confines of the specific discipline concerned. Nature also publishes Reviews, as well as Editorials and other Opinion pieces, News and Features, News and Views, Books and Arts, and the science-fiction series, Futures. In addition, it features NatureJobs, a section on careers and recruitment, thematic supplements called Outlooks, and Technology Features. Nature publishes much online-only information, including the daily award-winning Nature News, and regular web-only collections of topical material. For more information: http://www.
Nature Medicine is a biomedical research journal devoted to publishing the latest and most exciting advances in biomedical research for scientists and physicians. It publishes in fields such as infectious disease, cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and neuroscience. We are proud to present unique events (some in concert with specific institutions) that will become essential resources for the researchers of today and tomorrow. For more information: http://www.
Nature Reviews Molecular Cell Biology aims to be the premier source of reviews and commentaries for the scientific communities we serve. We strive to publish articles that are authoritative, accessible and enhanced with clearly understandable figures, tables and other display items. We want to provide an unparalleled service to authors, referees and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Reviews, Perspectives, Comments and Research Highlights relevant to molecular and cell biologists, with our broad scope ensuring that the articles we publish reach the widest possible audience. For more information: https:/